Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 18/20 | 0.66 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.56 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | PPARG | P37231 | 1/20 | 0.43 |
| ▸ | NCOA2 | Q15596 | 1/20 | 0.43 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.43 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14340848 | 0.91 | HCAR2 (0.79) | HCAR2CYP2C9 | |
| SCHEMBL14340940 | 0.87 | TP53 (0.54) | HCAR2CYP2C9TP53ALDH1A1 | |
| SCHEMBL13933802 | 0.79 | HCAR2 (1.00) | HCAR2CYP2C9 | |
| SCHEMBL4548471 | 0.78 | HCAR2 (0.70) | HCAR2CYP2C9 | |
| SCHEMBL4548475 | 0.78 | HCAR2 (0.64) | HCAR2CYP2C9 | |
| SCHEMBL4554984 | 0.76 | HCAR2 (0.57) | HCAR2CYP2C9 | |
| SCHEMBL4548335 | 0.75 | HCAR2 (1.00) | HCAR2CYP2C9 | |
| SCHEMBL4548469 | 0.73 | HCAR2 (0.83) | HCAR2CYP2C9 | |
| SCHEMBL4548342 | 0.73 | HCAR2 (0.83) | HCAR2CYP2C9 | |
| SCHEMBL10312776 | 0.72 | HCAR2 (0.64) | HCAR2CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070281969-A1 | Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment | MERCK SHARP & DOHME CORP. | 2007-12-06 | — | — | US | disclosed |
| US-20070281969-A1 | Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment | MERCK SHARP & DOHME CORP. | 2007-12-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070281969-A1 | Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment | GPR119, FFAR1, HCAR1 | HCAR2 7/4885CYP2C9 768/4885TP53 3695/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.